Note that some links may require subscriptions.
Everyone knows about the placebo effect, but how about the nice-doctor effect? (New York Times)
The effect of listing drug prices in television commercials might be undercut if pharma companies can tell patients that their insurers will foot most of the bill. (CNN)
Various squash and other veggies get leading roles in a new Peyronie’s disease commercial. (FiercePharma)
One of the doctors overseeing care of the incapacitated patient who became pregnant at the Hacienda Healthcare facility in Arizona has resigned, while another has been suspended. (CBS News)
PhRMA, or the Pharmaceutical Research and Manufacturers of America, breaks its previous lobbying high, spending a whopping $27.5 million on efforts to influence lawmakers last year. (The Hill)
Direct-to-consumer 23andMe test gets FDA clearance for determining whether individuals have a gene putting them at risk for a rare type of hereditary colorectal cancer. (Time)
The FDA needs to be brought back up to full capacity immediately, 46 medical groups said in a letter to congressional leaders.
Under a new Trump administration proposal, patients on the healthcare exchanges could face higher out-of-pocket costs if they opt for brand-name drugs when generics exist … (Becker’s Hospital Review)
… though some secret rebate agreements block generics from ever making it to patients. (Kaiser Health News)
Wearable technology is expected to play a major role in earlier diagnosis of psychiatric disorders in children. (Global Data)
Final tally? CDC says there were 201 confirmed acute flaccid myelitis (AFM) cases across 40 states in 2018.
Overweight kids with non-alcoholic fatty liver disease (NAFLD) had quick reductions in liver fat and inflammation when they cut sugar out of their diets. (JAMA)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]